Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Ascendis Pharma (ASND – Research Report). The associated ...

TransCon CNP matches BioMarin's Voxzogo for achondroplasia with plans for regulatory filings in 2025, showing potential for ...

Its EC approval came in 2022. Presentation slide 10 describes its revenue and planned development: Its hypoparathyroidism therapy, YORVIPATH (Palopegteriparatide, developed as TransCon PTH ...

CEO Jan Mikkelsen expressed confidence in the company’s growth trajectory, reporting estimated revenues of €202 million for SKYTROFA in 2024, and €29 million for YORVIPATH, with significant ...

We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a ...

COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones.

“Ascendis is well-positioned for rapid revenue growth with the launch of our first two Endocrinology Rare Disease medicines, SKYTROFA and YORVIPATH, and, following our pre-NDA meeting, planned ...

“Ascendis is well-positioned for rapid revenue growth with the launch of our first two Endocrinology Rare Disease medicines, SKYTROFA and YORVIPATH, and, following our pre-NDA meeting, planned filings ...